ONCO Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
17.1K
-20.2%
21.5K
-92.9%
303.6K
-0.0%
303.7K
+185.1%
106.5K
Cost of Revenue
12.8K
-44.5%
23.1K
-58.7%
55.9K
+60.9%
34.8K
-3.4%
36.0K
Gross Profit
4.3K
+360.0%
-1655
-100.7%
247.7K
-7.9%
268.9K
+281.4%
70.5K
Operating Expenses
2.7M
-73.2%
10.2M
+568.7%
1.5M
-34.6%
2.3M
+16.6%
2.0M
R&D
3.4K
-93.2%
50.8K
+109.2%
24.3K
+856.6%
-3211
+97.1%
-111670
SG&A
2.2M
+10.1%
2.0M
+35.5%
1.5M
-35.7%
2.3M
+53.7%
1.5M
Operating Income
-2730790
+73.3%
-10225801
-698.0%
-1281367
+38.1%
-2069242
-6.9%
-1935418
EBITDA
-2242158
-7.5%
-2086403
-63.3%
-1278031
+38.1%
-2065855
-54.4%
-1337719
Net Income
-2867303
+32.0%
-4214875
-174.3%
5.7M
+164.5%
-8783702
-270.2%
-2372442
EPS (Basic)
$-1.28
+98.1%
$-67.10
-137.0%
$181.27
+158.0%
$-312.50
-31.4%
$-237.91
EPS (Diluted)
$-1.28
+98.1%
$-67.10
-137.0%
$181.27
+158.0%
$-312.50
-31.4%
$-237.91
Shares (Diluted)
2.2M
+3468.3%
62.9K
+101.0%
31.3K
+11.3%
28.1K
+147.6%
11.4K
Onconetix (ONCO) โ€” Financials